AMN Stock Analysis: AMN Healthcare | NYSE
Medical Care Facilities | NYSE, USA | Market Cap: 1.348m USD | 12M Return: 63.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 31.0M
EPS Trend: -92.9%
Qual. Beats: 1
Rev. Trend: -79.7%
Qual. Beats: 3
Warnings
No concerns identified
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
AMN Healthcare Services, Inc. is a U.S.-based provider of technology-enabled healthcare workforce solutions and staffing services, serving acute and sub-acute care hospitals, skilled nursing facilities, rehabilitation clinics, schools, pharmacies, and other healthcare facilities. Founded in 1985 and headquartered in Dallas, Texas, the company operates through three reportable segments: Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions.
Its service portfolio spans travel nurse staffing, allied health staffing, crisis and labor disruption staffing, international nurse permanent placement, locum tenens, physician and advanced practice staffing, healthcare interim leadership, executive search, revenue cycle solutions, and language services. AMN also delivers vendor management systems (VMS), workforce optimization tools, and outsourced solutions, including its teletherapy platform, Televate, for K-12 schools. The healthcare staffing sector in which AMN operates is shaped by persistent clinical labor shortages, an aging patient population, and growing reliance on contingent labor to flex hospital capacity, which has made outsourced workforce management and VMS platforms a significant component of the broader health care services industry. AMN markets its offerings under brands such as AMN Healthcare, Nursefinders, OGrady Peyton International, Connetics, Medical Search International, DRW Healthcare Staffing, and B.E. Smith.
- Travel nurse demand and bill rates normalize from pandemic highs
- Nurse staffing volumes drive consolidated quarterly revenue
- Vendor management systems scale within Workforce Solutions segment
| Net Income: -32.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.27 > 0.02 and ΔFCF/TA 16.31 > 1.0 |
| NWC/Revenue: 2.70% < 20% (prev 1.58%; Δ 1.12% < -1%) |
| CFO/TA 0.28 > 3% & CFO 739.2m > Net Income -32.4m |
| Net Debt (250.6m) to EBITDA (201.6m): 1.24 < 3 |
| Current Ratio: 1.09 > 1.5 & < 3 |
| Outstanding Shares: last quarter (39.1m) vs 12m ago 2.10% < -2% |
| Gross Margin: 27.63% > 18% (prev 28.64%; Δ -1.01% > 0.5%) |
| Asset Turnover: 136.8% > 50% (prev 119.1%; Δ 17.69% > 0%) |
| Interest Coverage Ratio: 1.23 > 6 (EBIT TTM 49.2m / Interest Expense TTM 40.0m) |
| A: 0.04 (Total Current Assets 1.14b - Total Current Liabilities 1.04b) / Total Assets 2.60b |
| B: 0.49 (Retained Earnings 1.27b / Total Assets 2.60b) |
| C: 0.02 (EBIT TTM 49.2m / Avg Total Assets 2.50b) |
| D: 0.38 (Book Value of Equity 712.8m / Total Liabilities 1.89b) |
| Altman-Z'' = 2.35 = BBB |
| DSRI: 0.75 (Receivables 442.2m/493.3m, Revenue 3.42b/2.85b) |
| GMI: 1.04 (GM 28.64% / 27.63%) |
| AQI: 0.78 (AQ_t 0.51 / AQ_t-1 0.65) |
| SGI: 1.20 (Revenue 3.42b / 2.85b) |
| TATA: -0.30 (NI -32.4m - CFO 739.2m) / TA 2.60b) |
| Beneish M = -3.22 (Cap -4..+1) = AA |
As of July 06, 2026, the stock is trading at USD 34.75 with a total of 862,300 shares traded. Over the past week, the price has changed by +7.49%, over one month by +9.66%, over three months by +87.23% and over the past year by +63.68%.
Current recommended Stop Loss: 31.00 (which is 10.8% or 2.5 ATR below the current price).
AMN Healthcare has received a consensus analysts rating of 3.33. Therefore, it is recommended to hold AMN.
- StrongBuy: 1
- Buy: 2
- Hold: 5
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 29.9 | -14.1% |
P/E Forward = 26.178
P/S = 0.3942
P/B = 1.8087
P/EG = 1.7113
Revenue TTM = 3.42b USD
EBIT TTM = 49.2m USD
EBITDA TTM = 201.6m USD
Long Term Debt = 742.5m USD (from longTermDebt, last quarter)
Short Term Debt = 5.80m USD (from shortTermDebt, last quarter)
Debt = 811.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 34.4m
Net Debt = 250.6m USD (calculated: Debt 811.3m - CCE 560.7m)
Enterprise Value = 1.60b USD (1.35b + Debt 811.3m - CCE 560.7m)
Interest Coverage Ratio = 1.23 (Ebit TTM 49.2m / Interest Expense TTM 40.0m)
EV/FCF = 2.26x (Enterprise Value 1.60b / FCF TTM 706.3m)
FCF Yield = 44.19% (FCF TTM 706.3m / Enterprise Value 1.60b)
FCF Margin = 20.66% (FCF TTM 706.3m / Revenue TTM 3.42b)
Net Margin = -0.95% (Net Income TTM -32.4m / Revenue TTM 3.42b)
Gross Margin = 27.63% ((Revenue TTM 3.42b - Cost of Revenue TTM 2.47b) / Revenue TTM)
Gross Margin QoQ = 26.76% (prev 26.08%)
Tobins Q-Ratio = 0.61 (Enterprise Value 1.60b / Total Assets 2.60b)
Interest Expense / Debt = 4.93% (Interest Expense 40.0m / Debt 811.3m)
Taxrate = 43.72% (48.3m / 110.5m)
NOPAT = 27.7m (EBIT 49.2m * (1 - 43.72%))
Current Ratio = 1.09 (Total Current Assets 1.14b / Total Current Liabilities 1.04b)
Debt / Equity = 1.14 (Debt 811.3m / totalStockholderEquity, last quarter 712.8m)
Debt / EBITDA = 1.24 (Net Debt 250.6m / EBITDA 201.6m)
Debt / FCF = 0.35 (Net Debt 250.6m / FCF TTM 706.3m)
Total Stockholder Equity = 651.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -1.30% (Net Income -32.4m / Total Assets 2.60b)
RoE = -4.98% (Net Income TTM -32.4m / Total Stockholder Equity 651.7m)
RoCE = 3.53% (EBIT 49.2m / Capital Employed (Equity 651.7m + L.T.Debt 742.5m))
RoIC = 1.98% (NOPAT 27.7m / Invested Capital 1.40b)
WACC = 6.75% (E(1.35b)/V(2.16b) * Re(9.14%) + D(811.3m)/V(2.16b) * Rd(4.93%) * (1-Tc(0.44)))
Discount Rate = 9.14% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 1.10%
[DCF] Terminal Value 77.97% ; FCFF base≈527.4m ; Y1≈604.6m ; Y5≈889.8m
[DCF] Fair Price = 338.8 (EV 13.4b - Net Debt 250.6m = Equity 13.1b / Shares 38.8m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -92.87 | EPS CAGR: -49.23% | SUE: 4.0 | # QB: 1
Revenue Correlation: -79.72 | Revenue CAGR: -13.37% | SUE: 4.0 | # QB: 3
EPS current Quarter (2026-06-30): EPS=0.19 | Chg30d=+0.00% | Revisions=+75% | Analysts=9
EPS next Quarter (2026-09-30): EPS=0.17 | Chg30d=+0.00% | Revisions=-8% | Analysts=9
EPS current Year (2026-12-31): EPS=2.66 | Chg30d=+0.00% | Revisions=+75% | GrowthEPS=+95.7% | GrowthRev=+19.1%
EPS next Year (2027-12-31): EPS=1.09 | Chg30d=+0.00% | Revisions=-18% | GrowthEPS=-59.2% | GrowthRev=-19.9%
[Analyst] Revisions Ratio: +39% (up=25, down=10)